679 related articles for article (PubMed ID: 8732377)
1. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
[TBL] [Abstract][Full Text] [Related]
2. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM
Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348
[TBL] [Abstract][Full Text] [Related]
3. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
GUSTO Angiographic Investigators
N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
[TBL] [Abstract][Full Text] [Related]
5. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
Singh N; Mironov D; Armstrong PW; Ross AM; Langer A
Circulation; 1996 Apr; 93(7):1388-95. PubMed ID: 8641028
[TBL] [Abstract][Full Text] [Related]
6. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM
J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505
[TBL] [Abstract][Full Text] [Related]
7. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
[TBL] [Abstract][Full Text] [Related]
9. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
Goodman SG; Langer A; Ross AM; Wildermann NM; Barbagelata A; Sgarbossa EB; Wagner GS; Granger CB; Califf RM; Topol EJ; Simoons ML; Armstrong PW
Circulation; 1998 Feb; 97(5):444-50. PubMed ID: 9490238
[TBL] [Abstract][Full Text] [Related]
10. TIMI grade flow, mortality, and the GUSTO-III trial.
Stringer KA
Pharmacotherapy; 1998; 18(4):699-705. PubMed ID: 9692644
[TBL] [Abstract][Full Text] [Related]
11. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW
J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706
[TBL] [Abstract][Full Text] [Related]
12. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
Bates ER
Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479
[TBL] [Abstract][Full Text] [Related]
13. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Kleiman NS; White HD; Ohman EM; Ross AM; Woodlief LH; Califf RM; Holmes DR; Bates E; Pfisterer M; Vahanian A
Circulation; 1994 Dec; 90(6):2658-65. PubMed ID: 7994805
[TBL] [Abstract][Full Text] [Related]
14. Thrombolytic therapy reduces the incidence of left ventricular thrombus after anterior myocardial infarction. Relationship to vessel patency and infarct size.
Pizzetti G; Belotti G; Margonato A; Carlino M; Gerosa S; Carandente O; Chierchia SL
Eur Heart J; 1996 Mar; 17(3):421-8. PubMed ID: 8737217
[TBL] [Abstract][Full Text] [Related]
15. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.
Woodfield SL; Lundergan CF; Reiner JS; Greenhouse SW; Thompson MA; Rohrbeck SC; Deychak Y; Simoons ML; Califf RM; Topol EJ; Ross AM
J Am Coll Cardiol; 1996 Dec; 28(7):1661-9. PubMed ID: 8962549
[TBL] [Abstract][Full Text] [Related]
16. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
17. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
[TBL] [Abstract][Full Text] [Related]
18. Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Gulba DC; Tanswell P; Dechend R; Sosada M; Weis A; Waigand J; Uhlich F; Hauck S; Jost S; Rafflenbeul W; Lichtlen PR; Dietz R
J Am Coll Cardiol; 1997 Dec; 30(7):1611-7. PubMed ID: 9385884
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
[TBL] [Abstract][Full Text] [Related]
20. Accelerated infusion of streptokinase in acute myocardial infarction results in better TIMI flow grade in infarct-related artery.
Dwivedi SK; Saran RK; Narain VS; Bansal S; Gupta R; Puri VK
Indian Heart J; 2000; 52(1):40-4. PubMed ID: 10820932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
